Joshua Gottsegen, MD
Cardiovascular Disease · Wellington, FLNPI 1902923550
Payments from drug & device makers
Across 327 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Abbott$877
- Amgen$712
- E.r. Squibb & Sons, L.L.C.$627
- Novartis$547
- Johnson & Johnson$439
- plus $2K from 24 others
What the payments were for
- Travel & lodging$75712%
- Food & beverage$5,29887%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,164 |
| Abbott | 34 | $877 |
| Amgen | 74 | $712 |
| E.r. Squibb & Sons, L.L.C. | 56 | $627 |
| Novartis | 31 | $547 |
| Johnson & Johnson | 39 | $439 |
| Medtronic(2 entities) | 5 | $229 |
| Pfizer | 13 | $208 |
| Sanofi-aventis U.S. LLC | 10 | $189 |
| Boehringer Ingelheim | 8 | $148 |
| Kestra Medical Technology Services, Inc. | 2 | $107 |
| Cvrx, Inc. | 6 | $105 |
| AstraZeneca | 6 | $86 |
| Novo Nordisk | 3 | $79 |
| Abiomed | 3 | $76 |
| Alnylam Pharmaceuticals Inc. | 4 | $74 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $59 |
| Heartflow, Inc. | 2 | $58 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Bayer | 2 | $30 |
| Acutus Medical, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Inari Medical, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$1,033
- AVEIR$250
- CLARIA MRI QUAD CRT-D SURESCAN$174
- CAMZYOS$125
- Quadra Assura CRT Defibrillator$106
How this compares
$6,101 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 426 | $366,154 |
| EntrestoSacubitril/Valsartan | 147 | $163,227 |
| XareltoRivaroxaban | 95 | $101,955 |
| Repatha SureclickEvolocumab | 88 | $67,852 |
| BrilintaTicagrelor | 56 | $35,071 |
| NexletolBempedoic Acid | 35 | $28,394 |
| NexlizetBempedoic Acid/Ezetimibe | 46 | $27,665 |
| MultaqDronedarone Hcl | 12 | $19,860 |
| JardianceEmpagliflozin | 20 | $16,448 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 29 | $7,476 |
| Metoprolol Succinate | 475 | $6,148 |
| Nebivolol Hcl | 78 | $3,261 |
| Nifedipine ErNifedipine | 102 | $3,015 |
| Atorvastatin Calcium | 242 | $2,152 |
| Midodrine Hcl | 31 | $1,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $208 | $366,154426 claims |
| NovartisEntresto | $547 | $163,227147 claims |
| Johnson & JohnsonXarelto | $439 | $101,95595 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $71 | $56,06081 claims |
| AstraZenecaBrilinta | $86 | $35,07156 claims |
| Sanofi-aventis U.S. LLCMultaq | $189 | $19,86012 claims |
| Boehringer IngelheimJardiance | $148 | $16,44820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Wellington
- Duccio BaldariWellington$3.5M
- Jean FoucauldWellington$3.5M
- Neerav ShahWellington$2.1M
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.